Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...

TTAM will acquire substantially all of 23andMe’s assets for $305 million, including its Personal Genome Service and Research ...

Anne Wojcicki, co-founder and former CEO of 23andMe, will regain control of the embattled genetic testing company through a ...

Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...

Me filed for bankruptcy in March, seeking to sell its business at auction after a decline in consumer demand and a 2023 data ...

Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second ...

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a ...

Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

TTAM Research Institute, a nonprofit public benefit corporation based in California and led by 23andMe co-founder and former ...